Ashfield, part of UDG Healthcare, has launched EmerGENE, a global end-to-end cell and gene therapy network approach designed to support small and midsize biotechs with the commercialization of their discoveries.
EmerGENE has been built by a multidisciplinary team that delivers expert-led guidance and services to biotechs throughout their entire clinical to commercial journey.
Combining experts from Ashfield Health, Ashfield Engage, and Ashfield Advisory, EmerGENE aims to unlock the potential of cell and gene therapy, helping drug developers to bring transformational treatments to patients.
